Your session is about to expire
← Back to Search
Dapagliflozin for Heart Attack Recovery
Study Summary
This trial will test if dapagliflozin can improve heart function and reduce enlargement after a heart attack. Participants will take the medication or a placebo once daily for six months and have follow-up MRI tests and clinic visits.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had heart bypass or valve surgery in the past.You are not expected to live for more than 1 year.You have a specific type of heart damage that is more than 10% of the size of the heart attack.I have had a major heart attack before.I am currently experiencing unresolved cardiogenic shock.My kidney function is very low or I am on dialysis.You have a condition that makes it unsafe for you to receive gadolinium.I am between 18 and 75 years old, had a first heart attack, and underwent a successful procedure to open my heart's arteries.You are not able to have a cardiac MRI for medical reasons.I have irregular heartbeats or repeated serious heart rhythm problems.I have type 1 diabetes or have had diabetic ketoacidosis.I have diabetes and use insulin.You had an allergic reaction to SGLT2 inhibitors before.I am currently taking SGLT2 inhibitors.You have a weak heart with a low ejection fraction (LVEF < 50%) as shown in heart tests.The size of the heart attack is more than 10% of the total mass of the left ventricle.
- Group 1: Treatment Group
- Group 2: Placebo Group
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the enrolment for this experiment restricted to adults aged 55 or below?
"Prospective participants must fall into the age range of 18-75 years old to qualify for this research trial."
What potential perils are posed by Treatment Group to those who partake?
"After careful consideration, Treatment Group's safety rating was determined to be a 2 due to limited evidence supporting efficacy. However, there is some data that speaks in favor of the drug's security profile."
Is this research accepting new participants at present?
"Affirmative. Per the data available on clinicaltrials.gov, this examination is actively recruiting as of August 4th 2022 after being initially posted on March 8th 2022. The trial requires 80 volunteers to be enrolled at a single medical site."
What is the participant count of this research endeavor?
"Affirmative. According to clinicaltrials.gov, this medical study is recruiting patients right now; the initial posting was on August 3rd 2022 and a recent update occurred on August 4th 2022. 80 participants must be sourced from 1 site for successful completion of the trial."
Who has the qualifications to join this experimental program?
"To participate in this medical trial, individuals must have experienced a myocardial infarction and be between 18 to 75 years of age. A total of 80 candidates are needed for the study."
Share this study with friends
Copy Link
Messenger